Comparison of the long-term outcomes of uncinate process cancer and non-uncinate process pancreas head cancer: Poor prognosis accompanied by early locoregional recurrence

Langenbeck's Archives of Surgery

Volumn 395, Issue 6, 2010, Pages 697-706

  Kang, Mee Joo ^a   Jang, Jin Young ^a   Lee, Seung Eun ^a   Lim, Chang Sup ^a   Lee, Kuhn Uk ^a   Kim, Sun Whe ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Pancreatic cancer; Recurrence; Survival analysis

Indexed keywords

CAPECITABINE; CISPLATIN; FLUOROURACIL; GEMCITABINE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; JAUNDICE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTIPLE CYCLE TREATMENT; OPERATION DURATION; OUTCOME ASSESSMENT; PANCREAS CANCER; PANCREATICODUODENECTOMY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; SUPERIOR MESENTERIC ARTERY; SURGICAL MORTALITY; UNCINATE PROCESS PANCREAS CANCER; WEIGHT REDUCTION;

AGED; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PANCREAS; PANCREATIC NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84755161045     PISSN: 14352443     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00423-010-0593-6     Document Type: Article

References (32)

1. Yamaguchi K (1992) Carcinoma of the uncinate process of the pancreas with a peculiar clinical manifestation. Am J Gastroenterol 87:1046-1050
2. Ye C, Xi PC, Hu XG (2003) Clinical analysis of uncinate process carcinoma of the pancreas. Hepatobiliary Pancreat Dis Int 2:605-608
3. Suzuki T, Kuratsuka H, Uchida K, Matsumoto Y, Honjo I (1972) Carcinoma of the pancreas arising in the region of the uncinate process. Cancer 30:796-800
4. Li S, Pei YQ, Du FT, Ahuang GY, Li CY, Song QH et al (2002) Surgical treatment for uncinate process carcinoma of the pancreas. Hepatobiliary Pancreat Dis Int 1:592-594
5. Birk D, Schoenberg MH, Gansauge F, Formentini A, Fortnagel G, Beger HG (1998) Carcinoma of the head of the pancreas arising from the uncinate process. Br J Surg 85:498-501
6. O'Rahilly R, Muller F (1978) A model of the pancreas to illustrate its development. Acta Anat (Basel) 100:380-385
7. Kitagawa H, Ohta T, Makino I, Tani T, Tajima H, Nakagawara H et al (2008) Carcinomas of the ventral and dorsal pancreas exhibit different patterns of lymphatic spread. Front Biosci 13:2728-2735
8. Makino I, Kitagawa H, Ohta T,NakagawaraH, TajimaH,Ohnishi I et al (2008) Nerve plexus invasion in pancreatic cancer: spread patterns on histopathologic and embryological analyses. Pancreas 37:358-365
9. Atri M, Nazarnia S, Mehio A, Reinhold C, Bret PM (1994) Hypoechogenic embryologic ventral aspect of the head and uncinate process of the pancreas: in vitro correlation of US with histopathologic findings. Radiology 190:441-444
10. Inoue Y, Nakamura H (1997) Aplasia or hypoplasia of the pancreatic uncinate process: comparison in patients with and patients without intestinal nonrotation. Radiology 205:531-533 (Pubitemid 27467337)
11. Seo HB, Lee JM, Kim IH, Kim SH (2009) Evaluation of the gross type and longitudinal extent of extrahepatic cholangiocarcinomas on contrast-enhanced multidetector row computed tomography. J Comput Assist Tomogr 33:376-382
12. Han SS, Kim SW, Choi JI, Choi MG, Park YC, Jang JY, Park YH (2005) Determination of resectability for pancreatic cancer: based on the suspected vascular invasion in abdominal computed tomography. Korean J HBP Surg 9:55-61
13. Han SS, Jang JY, Kim SW, Kim WH, Lee KU, Park YH (2006) Analysis of long-term survivors after surgical resection for pancreatic cancer. Pancreas 32:271-275
14. Griffin JF, Smalley SR, Jewell W, Paradelo JC, Reymond RD, Hassanein RE (1990) Patterns of failure after curative resection of pancreatic carcinoma. Cancer 66:56-61
15. Barugola G, Falconi M, Bettini R, Boninsegna L, Casarotto A (2007) The determinant factors of recurrence following resection for ductal pancreatic cancer. JOP 9:132-140
16. Verbeke CS, Leitch D, Menon KV, McMahon MJ, Guillou PJ, Anthoney A (2006) Redefining the R1 resection in pancreatic cancer. Br J Surg 93:1232-1237
17. Westgaard A, Tafjord S, Farstad IN, Cvancarova M, Eide TJ, Mathisen O et al (2008) Resectable adenocarcinomas in the pancreatic head: the retroperitoneal resection margin is an independent prognostic factor. BMC Cancer 8:5
18. Esposito I, Kleeff J, Berqmann F, Reiser C, Herpel E, Friess H et al (2008) Most pancreatic cancer resections are R1 resections. Ann Surg Oncol 15:1651-1660
19. American Joint Committee on Cancer (2002) Exocrine pancreas. In: AJCC cancer staging manual. Springer, New York, 157-164
20. Raut CP, Tseng JF, Sun CC, Wang H, Wolff RA, Crane CH et al (2007) Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 246:52-60
21. Haslam JB, Cavanaugh PJ, Stroup SL (1973) Radiation therapy in the treatment of irresectable adenocarcinoma of the pancreas. Cancer 32:1341-1345
22. Moertel CG, Childs DS Jr, Reitemeir RJ, Colby MY Jr, Holbrook MA (1967) Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 2:865-867
23. Moertel CG, Frytak S, Hahn RG, O'Connell MJ, Reitemeier RJ (1981) Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads+5-fluorouracil), and high dose radiation + 5-fluorouracil. The Gastrointestinal Study Group. Cancer 48:1705-1710
24. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H et al (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350:1200-1210
25. Klinkenbijil JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH et al (1999) Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region. Phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg 230:776-784
26. Chu QD, Khushalani N, Javle MM, Douglas HO Jr, Gibbs JF (2003) Should adjuvant therapy remain the standard of care for patinets with resected adenocarcinoma of the pancreas? Ann Surg Oncol 10:539-545
27. Kennedy EP, Yeo CJ (2007) The case for routine use of adjuvant therapy in pancreatic cancer. J Surg Oncol 95:597-603
28. Stocken DD, Büchler MW, Dervenis C, Bassi C, Jeekel H, Klinkenbijl JHG et al (2005) Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer 92:1372-1381
29. National Comprehensive Cancer Network. Practice guidelines in oncology. http://www.nccn.org
30. Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A et al (2008) Fluorouracil vs. gemcitabine chemotherapy before and after fluorouracil-based chemoradiation after resection of pancreatic adenocarcinoma. A randomized controlled trial. JAMA 299:1019-1026
31. Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schonekas H, Rost A et al (2006) Randomized phase iii trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24:3946-3952
32. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966